- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-418/21: Order of the General Court of 14 January 2022 — Alauzun and Others v Commission and EMA (Action for annulment — Medicinal products for human use — Amendment to the conditional marketing authorisation for the medicinal product for human use Comirnaty — Act not open to challenge — Preparatory act — No interest in bringing proceedings — No direct concern — Act not of individual concern — Non-regulatory act — Inadmissibility)
ECLI:EU:UNKNOWN:62021TB0418
62021TB0418
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 128/25
(Case T-418/21) (<span class="oj-super oj-note-tag">1</span>)
(Action for annulment - Medicinal products for human use - Amendment to the conditional marketing authorisation for the medicinal product for human use Comirnaty - Act not open to challenge - Preparatory act - No interest in bringing proceedings - No direct concern - Act not of individual concern - Non-regulatory act - Inadmissibility)
(2022/C 128/37)
Language of the case: French
Parties
Applicants: Virginie Alauzun (Saint-Cannat, France) and 774 other applicants whose names are set out in the annex to the order (represented by: F. Di Vizio, lawyer)
Defendants: European Commission (represented by: O. Beynet, L. Haasbeek and K. Mifsud-Bonnicci, acting as Agents), European Medicines Agency (represented by: S. Drosos, C. Schultheiss and S. Marino, acting as Agents)
Re:
Application under Article 263 TFEU for annulment, first, of Commission Implementing Decision C(2021) 4034 final of 31 May 2021 amending the conditional marketing authorisation granted by Implementing Decision C(2020) 9598 final for ‘Comirnaty — COVID-19 mRNA Vaccine (nucleoside modified)’, a medicinal product for human use, and, second, of the EMA’s opinion of 28 May 2021.
Operative part of the order
1.The action is dismissed as inadmissible.
2.Ms Virginie Alauzun and the other applicants whose names are set out in the annex shall pay the costs.
(<span class="oj-super">1</span>) OJ C 338, 23.8.2021.
* * *
Language of the case: French